Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: A systematic review

Internal Medicine Journal

Volumn 43, Issue 7, 2013, Pages 751-760

  Thakkar, V ^a,c   Stevens, W M ^a   Moore, O A ^a,d   Nikpour, M ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LIVERPOOL HOSPITAL   (Australia)

^d DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Early detection; Hypertension; Pulmonary; Scleroderma; Screening; Systemic

Indexed keywords

CARBON MONOXIDE;

ALGORITHM; ARTICLE; ECHOCARDIOGRAPHY; FOLLOW UP; HEART CATHETERIZATION; HUMAN; LUNG DIFFUSION CAPACITY; PREDICTIVE VALUE; PRESSURE GRADIENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCREENING; SCREENING TEST; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TRICUSPID VALVE REGURGITATION;

EARLY DETECTION; HYPERTENSION; PULMONARY; SCLERODERMA; SCREENING; SYSTEMIC;

ALGORITHMS; HUMANS; HYPERTENSION, PULMONARY; MASS SCREENING; OBSERVATIONAL STUDY AS TOPIC; SCLERODERMA, SYSTEMIC;

EID: 84880357893     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12167     Document Type: Article

References (39)

1. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P etal. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290-2298.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-944.
3. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE etal. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
4. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F etal. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2008; 179: 151-157.
5. Hachulla E, Launay D, Yaici A, Berezne A, de Groote P, Sitbon O etal. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology 2010; 49: 940-944.
6. Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB etal. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
7. Denton CP. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-1340.
8. Rubin L, Pulido T, Channick R, Delcroix M, Galie N, Ghofrani A etal. Effect of macicentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN trial. Chest 2012; 142: 1026A.
9. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D etal. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530.
10. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR etal. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. J Am Coll Cardiol 2009; 53: 1573-1619.
11. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA etal. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
12. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart 2008; 94(Suppl 1): i1-41.
13. Masi A. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
14. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-1576.
15. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-162.
16. NHMRC. How to review the evidence: systematic identification and review of the scientific literature [cited 2012 Aug 27]. Available from URL: http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp65.pdf
17. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E etal. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-291.
18. Cavagna L, Caporali R, Klersy C, Ghio S, Albertini R, Scelsi L etal. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37: 2064-2070.
19. Ciurzynski M, Bienias P, Irzyk K, Rymarczyk Z, Kostrubiec M, Szewczyk A etal. Usefulness of echocardiography in the identification of an excessive increase in pulmonary arterial pressure in patients with systemic sclerosis. Kardiol Pol 2011; 69: 9-15.
20. Frea S, Capriolo M, Marra WG, Cannillo M, Fusaro E, Libertucci D etal. Echo Doppler predictors of pulmonary artery hypertension in patients with systemic sclerosis. Echocardiography 2011; 28: 860-869.
21. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J etal. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800.
22. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P etal. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831-1839.
23. Jansa P, Becvar R, Ambroz D, Palecek T, Tomcik M, Skacelova S etal. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clin Rheumatol 2011; 31: 557-561.
24. Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J etal. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-1093.
25. Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK etal. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 2011; 63: 2456-2464.
26. Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM etal. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-577.
27. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP etal. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010; 37: 105-115.
28. Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE etal. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008; 35: 458-465.
29. Mathai SC, Sibley CT, Forfia PR, Mudd JO, Fisher MR, Tedford RJ etal. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol 2011; 38: 2410-2418.
30. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997; 36: 239-243.
31. Mukerjee D. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004; 43: 461-466.
32. Sanchez-Roman J, Opitz CF, Kowal-Bielecka O, Garcia-Hernandez FJ, Castillo-Palma MJ, Pittrow D. Screening for PAH in patients with systemic sclerosis: focus on Doppler echocardiography. Rheumatology 2008; 47: v33-35.
33. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888-894.
34. Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA etal. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. Arthritis Rheum 2010; 62: 3741-3750.
35. Steen VD, Champion H. Is exercise-induced pulmonary hypertension ready for prime time in systemic sclerosis? Int J Clin Pract 2011; 65: 1-3.
36. Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology (Oxford) 2011; 50: 762-767.
37. Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L etal. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211-1219.
38. Hinchcliff M, Fischer A, Schiopu E, Steen VD. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38: 2172-2179.
39. ClinicalTrials.gov. Early, simple and reliable detection of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). NCT00706082. Date last updated: June 21, 2012. [cited 2012 Aug 27]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00706082